AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
CEL-SCI Corp Insider Buying: CEO Geert Kersten Acquires Additional Shares
ByAinvest
Monday, Jul 28, 2025 1:40 pm ET1min read
Geert Kersten, CEO of CEL-SCI Corp, purchased 29,197 shares of the company on July 25, 2025, bringing his total ownership to 72,835 shares. This insider buying trend is positive, with 1 insider buy and 0 insider sells over the past year. CEL-SCI Corp's primary product, Multikine, is an investigational immunotherapy for head and neck cancer. The company has a market cap of $46.213 million, with shares trading at $6.85 each.
In a significant move, Geert Kersten, the CEO of CEL-SCI Corporation (CVM), purchased 29,197 shares of the company on July 25, 2025. This purchase, valued at $199,999, brings his total ownership to 72,835 shares. This insider buying trend is positive, with only one insider buy and no insider sells over the past year [1].The acquisition of these shares comes amidst CEL-SCI's ongoing research into Multikine, an investigational immunotherapy for head and neck cancer. The company's market capitalization stands at $46.213 million, with shares trading at $6.85 each [1].
The recent insider buying activity has sparked interest among investors, who are closely monitoring the company's progress in the biotech sector. The latest offering announcement by CEL-SCI, totaling $5.7 million, has also drawn attention. This capital raise is expected to fund critical clinical trials, reflecting the company's commitment to advancing its immunotherapy candidate [1].
Geert Kersten's purchase is notable as it is his first insider buy in the past twelve months. His confidence in the company's prospects is a positive signal to investors, as insider buying often indicates a belief in the company's future performance. The fact that no insider sales have been reported in the past year further underscores this positive sentiment [2].
CEL-SCI's recent financial moves, including the insider buying and the capital raise, indicate a strategic approach to funding research and development. As the company continues to make progress in its immunotherapy program, investors will be watching closely for further updates on how the funds will be utilized and how these developments might impact the stock price.
References:
[1] https://www.quiverquant.com/news/CEL-SCI+Corporation+Stock+%28CVM%29+Opinions+on+%245.7+Million+Offering+Announcement
[2] https://www.nasdaq.com/articles/monday-7-28-insider-buying-report-cvm-loop
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet